European guidance for the diagnosis and management of osteoporosis in postmenopausal women
By J. Kanis, Eugene V. McCloskey, H. Johansson, Chris Cooper, R. Rizzoli, J. Reginster, on behalf of the International Osteoporosis Foundation. Osteoporosis International, 2008
996 citations recorded by the source corpus.
SummaryGuidance is provided in a European setting on the assessment and treatment of postmenopausal women at risk of fractures due to osteoporosis.IntroductionThe International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published guidance for the diagnosis and management of osteoporosis in 2008. This manuscript updates these in a European setting.MethodsSystematic literature reviews.ResultsThe following areas are reviewed: the role of bone mineral density measurement for the diagnosis of osteoporosis and assessment of fracture risk, general and pharmacological management of osteoporosis, monitoring of treatment, assessment of fracture risk, case finding strategies, investigation of patients and health economics of treatment.ConclusionsA platform is provided on which specific guidelines can be developed for national use.
Subfields: Molecular Biology, Orthopedics and Sports Medicine, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/67b9bc1d34224eb269afdb2509dbc58f8aa27172
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Orthopedics and Sports Medicine
Citations in the corpus
- Denosumab and bisphosphonates: different mechanisms of action and effects. (2011, background): “In postmenopausal osteoporosis, rare cases of ONJ have been reported in both women receiving bisphosphonates as well as denosumab [64,170,173], but no causal association has been established.”